Investors must realise that what is done in a lab can genuinely impact the market potential of a business, says Dr Andrew Clark
One of the nicest things about being an investor in life science companies is that you are really investing in healthcare ' a market that inexorably grows over time. People do not stop being ill because there is a recession, and neither do they decide to buy a triple bypass just because the economy is booming. The demographics of the developed world point to an ageing population ' healthcare costs increase with age. At the same time, most healthcare is provided by governments and the political implications of any attempt to reduce the rate of increase in healthcare spending means few gove...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes